½ÃÀ庸°í¼­
»óǰÄÚµå
1403435

¼¼°èÀÇ ¿ø°Ý¾à±¹(Telepharmacy) ½ÃÀå ¿¹Ãø(-2030³â) : ¼­ºñ½ºº°, Á¦°ø ¸ðµåº°, µð¹ÙÀ̽ºº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®

Telepharmacy Market Forecasts to 2030 - Global Analysis By Service (Drug Therapy Monitoring, Patient Counselling and Other Services), By Delivery Mode (On-premises, Cloud-based and Web-based), Device, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é 2023³â ¼¼°è ¿ø°Ý¾à±¹ ½ÃÀåÀº 92¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 18.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 301¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ø°Ý¾à±¹Àº Åë½Å ¹× µðÁöÅÐ Ç÷§ÆûÀ» ÅëÇØ Á¦°øµÇ´Â ¿ø°Ý ÀǾàǰ ¼­ºñ½º¸¦ Æ÷°ýÇÕ´Ï´Ù. ¾à»ç°¡ ¿ø°ÝÀ¸·Î Åõ¾à »ó´ã, Ä¡·á °ü¸®, Á¶Á¦¸¦ ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¿ø°Ý¾à±¹Àº ƯÈ÷ ¼­ºñ½º ¼Ò¿Ü Áö¿ª¿¡¼­ ¾à±¹ ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í, º¹¾à ¼øÀÀµµ¸¦ ³ôÀ̰í, °¡»ó »ó´ãÀ» Á¦°øÇÔÀ¸·Î½á ¿ø°ÝÁö¿ÍÀÇ ±³·ù¿Í ±â¼ú ¼Ö·ç¼ÇÀ» ÅëÇØ ȯÀÚ °ü¸® ¹× º¹¾à Áö¿øÀ» Áö¿øÇÕ´Ï´Ù.

¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)ÀÇ Á¶»ç¿¡ µû¸£¸é, Äڷγª19 ÆÒµ¥¹Í »óȲ¿¡¼­ ¾à±¹À» Á÷Á¢ ¹æ¹®ÇÏ´Â °Í°ú ¿ø°Ý ¾à¹°Ä¡·á¿¡ ´ëÇÑ È¯ÀÚµéÀÇ »ý°¢°ú ¼±È£µµ¿¡ ´ëÇØ ÀÀ´äÀÚÀÇ ¾à 77%°¡ ¿ø°Ý ¾à¹°Ä¡·á¸¦ ÅëÇÑ ¿¹¾àÀ» ¼±È£ÇÑ´Ù°í ¹àÇû½À´Ï´Ù.

¿ø°Ý ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

¿ø°Ý ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¿ø°Ý¾à±¹ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Áö¸®Àû À庮, Á¦ÇÑµÈ ¾à±¹ Á¢±Ù¼º, Æí¸®ÇÑ ÀÇ·á ¼­ºñ½º ¿É¼ÇÀÇ Çʿ伺 µîÀÌ Æ¯È÷ ³óÃÌ ¹× ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ ÀÌ·¯ÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ¾à¹° Ä¡·á´Â ¾à¹° »ó´ã, Ä¡·á °ü¸®, ó¹æÀü º¸Ãæ°ú °°Àº ¿ø°Ý ¾à¹° ¼­ºñ½º¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù. Á¢±Ù¼º ¹× Àû½Ã¼º ÀÖ´Â ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¿ä±¸¿Í ÇÔ²² °¡»ó »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ¿ø°Ý¾à·á°¡ ¸Å¿ì Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿ø°Ý¾à·áÀÇ º¸±Þ°ú ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

´Ù¸¥ °üÇұǿ¡¼­ ¶óÀ̼±½º¸¦ ÃëµæÇϱâ À§ÇÑ µµÀü °úÁ¦

Áö¿ª°ú ÁÖ¸¶´Ù ´Ù¸¥ ±ÔÁ¦¿Í ¶óÀ̼±½º ¿ä°ÇÀº º¹ÀâÇÑ ±ÔÁ¤ Áؼö ÀýÂ÷¸¦ ¿ä±¸ÇÕ´Ï´Ù. ¿©·¯ °üÇұǿ¡ °ÉÃÄ ¿î¿µµÇ´Â ¿ø°Ý ¾à¹° Ä¡·á ¼­ºñ½º´Â Á¾Á¾ ¾ö°ÝÇÑ ¸éÇã Ãëµæ ÀýÂ÷¸¦ °ÅÃÄ¾ß ÇÏ´Â ´Ù¾çÇÑ ¹ýÀû ü°è¸¦ °ÅÃÄ¾ß ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¼­·Î ´Ù¸¥ ±ÔÁ¦¸¦ ÁؼöÇØ¾ß ÇÏ´Â °ÍÀº ¾÷¹«¸¦ º¹ÀâÇÏ°Ô ¸¸µé°í °ü¸® ºÎ´ãÀ» Áõ°¡½ÃÄÑ ºü¸¥ ½ÃÀå È®ÀåÀ» ¹æÇØÇÕ´Ï´Ù. ¿©·¯ °üÇұǿ¡ °ÉÃÄ ´Ù¾çÇÑ ¶óÀ̼±½º ¿ä°ÇÀ» Åë°úÇØ¾ß ÇÏ´Â ÀÌ °úÁ¦´Â ¿ø°Ý ¾à¹° Ä¡·á ¼­ºñ½ºÀÇ ¿øÈ°ÇÑ Á¦°øÀ» ¹æÇØÇϰí Áö¸®Àû µµ´Þ ¹üÀ§¿Í È®À强À» Á¦ÇÑÇÕ´Ï´Ù.

¿ø°Ý ¾à¹°Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í

¿ø°Ý ¾à¹°Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå¿¡´Â Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¼Ö·ç¼ÇÀÌ È¯ÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü »çÀÌ¿¡¼­ È®´ëµÊ¿¡ µû¶ó ¿ø°Ý¾à±¹ÀÌ Á¦°øÇÏ´Â ÀÌÁ¡, ƯÈ÷ ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ ÀǾàǰ ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó, ¾à¹° °ü¸® °­È­, ÀÇ·á ¹üÀ§ È®´ë µîÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀº ¿ø°Ý ¾à¹° Ä¡·á ¼Ö·ç¼ÇÀÇ ¼ö¿ë°ú äÅÃÀ» ÃËÁøÇϰí ȯÀÚ¿Í ÀÇ·á ±â°ü ¸ðµÎ°¡ ¿ø°Ý ¼­ºñ½º¸¦ ¼ö¿ëÇϵµ·Ï Àå·ÁÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ¿ø°Ý ¾à¹° Ä¡·á ÀÌ´Ï¼ÅÆ¼ºêÀÇ ´õ ±¤¹üÀ§ÇÑ ±¸ÇöÀ» ÃËÁøÇÕ´Ï´Ù.

°³ÀÎ Á¤º¸ º¸È£ ¹× µ¥ÀÌÅÍ º¸¾È À§Çè

°íµµ·Î ¹Î°¨ÇÑ È¯ÀÚ Á¤º¸¸¦ ¿ø°ÝÀ¸·Î Ãë±ÞÇÏ´Â °ÍÀº »çÀ̹ö À§Çù, µ¥ÀÌÅÍ À¯Ãâ ¹× ¹«´Ü ¾×¼¼½º¿¡ ´ëÇÑ Ãë¾à¼ºÀ» Áõ°¡½Ãŵ´Ï´Ù. ȯÀÚÀÇ ºñ¹ÐÀ» º¸È£ÇÏ°í ¾ö°ÝÇÑ °³ÀÎ Á¤º¸ º¸È£ ±ÔÁ¤À» ÁؼöÇÏ´Â °ÍÀÌ °¡Àå Áß¿äÇÑ °úÁ¦ÀÔ´Ï´Ù. ÀÇ·á µ¥ÀÌÅÍÀÇ À߸øµÈ Ãë±Þ ¹× ¹«´Ü °ø°³´Â ȯÀÚÀÇ ½Å·Ú¸¦ ÈѼÕÇÏ°í ¹ýÀû ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àֱ⠶§¹®¿¡ ½ÃÀå È®´ë¸¦ ´õ¿í ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19ÀÇ ´ëÀ¯ÇàÀº ¿ø°Ý ¾à¹° Ä¡·á ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» Å©°Ô °¡¼ÓÈ­Çß½À´Ï´Ù. ÀÌ À§±â´Â ¿ø°Ý ÀÇ·á Á¢±ÙÀÇ Çʿ伺À» °­Á¶ÇÏ°í ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý¾à±¹ ¼­ºñ½º¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ô¿´½À´Ï´Ù. ¹® ´ÝÈû, »çȸÀû °Å¸®µÎ±â, ÀÇ·á ½Ã¼³ Á¦ÇÑÀ¸·Î ÀÎÇØ ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â ¿ø°Ý Áø·á, ó¹æÀü º¸Ãæ, ¿ø°Ý¾à±¹ Ç÷§ÆûÀ» ÅëÇÑ ¿ø°Ý Áø·á, ó¹æÀü º¸Ãæ, ¾à¹° °ü¸®¸¦ ¼ö¿ëÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿äÀÇ ±ÞÁõÀº Ä¡·áÀÇ ¿¬¼Ó¼ºÀ» º¸ÀåÇÏ´Â ¿ø°Ý ¾à¹° Ä¡·áÀÇ ÀáÀç·ÂÀ» º¸¿©ÁÖ¸ç ¿ø°Ý ¾à¹° ¼­ºñ½º·ÎÀÇ Àå±âÀûÀÎ ÀüȯÀ» Çü¼ºÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È ȯÀÚ »ó´ã ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ȯÀÚ »ó´ã ºÐ¾ß´Â Åõ¾à °ü¸®¿Í ȯÀÚ Áß½É Ä¡·á¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ¿ø°Ý¾à±¹ ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ø°Ý ¾à¹°Ä¡·á´Â ȯÀÚ¿¡°Ô Á¾ÇÕÀûÀÎ º¹¾àÁöµµ, Åõ¾à Áö½Ã, ºÎÀÛ¿ë °ü¸® µîÀÇ ±ÇÇÑÀ» ºÎ¿©ÇÏ°í °³º° »ó´ãÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÇコÄɾ¼­ ȯÀÚ Âü¿©¿Í º¹¾à ¼øÀÀµµ°¡ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç, ƯÈ÷ ¸¸¼º Áúȯ°ú º¹ÀâÇÑ Ä¡·á¿¡ ´ëÇÑ ¿ø°Ý »ó´ã ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ¿ø°Ý¾à·áÀÇ ´É·ÂÀÌ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü »ó´ã¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ¼ö¿ä´Â ȯÀÚ »ó´ã ºÐ¾ß¸¦ ¹ßÀü½ÃŰ°í ¿ø°Ý¾à±¹ ¼­ºñ½º¸¦ ÅëÇØ È¿°úÀûÀÎ ÀǾàǰ °ü¸®¸¦ º¸ÀåÇÏ´Â °ÍÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â º´¿ø ºÐ¾ßÀÔ´Ï´Ù.

º´¿ø ºÐ¾ß´Â ÁøÈ­ÇÏ´Â ÀÇ·á ¿ªÇÐÀ¸·Î ÀÎÇØ ¿ø°Ý¾à±¹ ½ÃÀå¿¡¼­ Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿øÀº ȯÀÚ Ä¡·á¸¦ ÃÖÀûÈ­Çϰí, ¾à¹° °ü¸®¸¦ °£¼ÒÈ­Çϰí, ¿ø°ÝÁö¿¡¼­ ¼­ºñ½º¸¦ È®ÀåÇϱâ À§ÇØ ¿ø°Ý ¾à¹° Ä¡·á¸¦ Á¡Á¡ ´õ ¸¹ÀÌ Ã¤ÅÃÇϰí ÀÖ½À´Ï´Ù. º´¿ø ½Ã½ºÅÛ¿¡ ¿ø°Ý ¾à¹° Ä¡·á ¼Ö·ç¼ÇÀ» ÅëÇÕÇÏ¸é ¾à¹° ¼øÀÀµµ¸¦ ³ôÀ̰í, ƯÈ÷ Åð¿ø È¯ÀÚ³ª ¸¸¼º ÁúȯÀ» ¾Î°í Àִ ȯÀÚÀÇ °¡»ó Áø·á¸¦ ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿ø°Ý ¾à¹° Ä¡·á´Â ÀÇ·á ¼­ºñ½º Á¢±Ù¼ºÀ» °­È­Çϰí ÀçÀÔ¿øÀ²À» ³·Ã߸ç Áö¼ÓÀûÀÎ ¾à¹° Ä¡·á Áö¿øÀ» º¸ÀåÇϱ⠶§¹®¿¡ º´¿ø ºÐ¾ß°¡ Å©°Ô È®´ëµÉ °ÍÀÔ´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ±â¼ú ±â¹Ý Çõ½Å, ¼º¼÷ÇÑ ¿ø°Ý ÀÇ·á »óȲÀ¸·Î ÀÎÇØ ¿ø°Ý ¾à¹° Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ¿ø°Ý ¾à¹° Ä¡·áÀÇ Ã¤ÅÃÀ» Áö¿øÇϴ źźÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ ÀÚ¶ûÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇ·áºñ ÁöÃâ Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡, ÀÇ·á Á¢±Ù¼º °³¼±ÀÌ ¿ø°Ý ÀÇ·á ¼­ºñ½º ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á °üÇàÀÌ È®¸³µÇ¾î ÀÖ°í ±¤¹üÀ§ÇÑ µðÁöÅÐ ¿¬°á¼ºÀ» °®Ãá ºÏ¹Ì´Â ±â¼ú·Â°ú ÀÇ·á ¹ßÀüÀ» Ȱ¿ëÇϰí ÁøÈ­Çϴ ȯÀÚÀÇ ¿ä±¸¸¦ ÃæÁ·½ÃÅ´À¸·Î½á ¿ø°Ý ¾à¹° Ä¡·á¸¦ ÁÖµµÇÒ ¼ö ÀÖ´Â ¿©°ÇÀ» °®Ãß°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÀÎÇÁ¶ó È®´ë, µðÁöÅÐ ±â¼ú äÅà Áõ°¡, Á¢±Ù¼º ³ôÀº ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¿ø°Ý ¾à¹° Ä¡·á ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ø°Ý ¾à¹° Ä¡·á´Â ÀǾàǰ Àü¹® Áö½Ä¿¡ ´ëÇÑ Æí¸®ÇÑ Á¢±ÙÀ» Á¦°øÇÔÀ¸·Î½á ƯÈ÷ ¿ø°ÝÁöÀÇ Áö¸®Àû À庮À» ÇØ°áÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ Ã·´Ü ±â¼ú¿¡ Á¤ÅëÇÑ Àα¸¿Í È¿À²ÀûÀÎ ÀÇ·á Á¦°ø ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿ø°Ý ¾à·á ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇÏ°í ¾Æ½Ã¾ÆÅÂÆò¾çÀ» ¿ø°Ý ¾à·á ¼­ºñ½º¿¡¼­ À¯¸®ÇÑ ¼ºÀåÀÇ À§Ä¡¿¡ ³õÀÌ°Ô ÇÕ´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÇü ¿É¼Ç Áß Çϳª¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÇü Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå PorterÀÇ Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ¿ø°Ý¾à±¹ ½ÃÀå : ¼­ºñ½ºº°

  • ¾à¹° ¿ä¹ý ¸ð´ÏÅ͸µ
  • ȯÀÚ Ä«¿î¼¿¸µ
  • ó¹æ¾à º¸Ãæ ½ÂÀÎ
  • ¿ø°Ý Á¶Á¦
  • ±âŸ ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ ¿ø°Ý¾à±¹ ½ÃÀå : Á¦°ø ¸ðµåº°

  • ¿ÂÇÁ·¹¹Ì½º
  • Ŭ¶ó¿ìµå ±â¹Ý
  • À¥ ±â¹Ý

Á¦7Àå ¼¼°èÀÇ ¿ø°Ý¾à±¹ ½ÃÀå : µð¹ÙÀ̽ºº°

  • ÄÄÇ»ÅÍ
  • ½º¸¶Æ®Æù
  • ÅÂºí¸´°ú Ű¿À½ºÅ©

Á¦8Àå ¼¼°èÀÇ ¿ø°Ý¾à±¹ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • 1Â÷ÀÇ·á(Primary care) ¼¾ÅÍ
  • º´¿ø
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ¼¼°èÀÇ ¿ø°Ý¾à±¹ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ÁÖ¿ä ¹ßÀü

  • °è¾à/ÆÄÆ®³Ê½Ê/Çù¾÷/ÇÕÀÛÅõÀÚ(JV)
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦11Àå ±â¾÷ °³¿ä

  • Capsule Technologies
  • CPS Solutions, LLC
  • Digital Pharmacist Inc.
  • McKesson Ventures
  • Medication Review, Inc.
  • Medtel Communications
  • Omnicell, Inc.
  • PharmaPoint
  • PioneerRx
  • Pipeline Healthcare
  • TelePharm(Cardinal Health)
  • Transaction Data Systems, Inc.
  • ZipDrug
LSH 24.01.17

According to Stratistics MRC, the Global Telepharmacy Market is accounted for $9.2 billion in 2023 and is expected to reach $30.1 billion by 2030 growing at a CAGR of 18.4% during the forecast period. Telepharmacy encompasses remote pharmaceutical services delivered via telecommunications and digital platforms. It enables pharmacists to provide medication consultations, therapy management and dispensing remotely. Telepharmacy enhances accessibility to pharmacy services, especially in underserved regions, facilitates medication adherence, and offers virtual consultations, aiding in patient care and medication support through remote interactions and technological solutions.

According to the National Institute of Health (NIH) survey on patients' perspectives and preferences in adopting telepharmacy versus in-person visits to the pharmacy during the COVID-19 pandemic, about 77% of respondents preferred appointments via telepharmacy.

Market Dynamics:

Driver:

Growing demand for remote healthcare solutions

The increasing demand for remote healthcare solutions drives the telepharmacy market. Factors such as geographic barriers, limited access to pharmacies and the need for convenient healthcare options, especially in rural or underserved areas, fuel this demand. Telepharmacy addresses these challenges by offering remote pharmaceutical services, including medication consultations, therapy management, and prescription refills. The growing preference for virtual interactions, coupled with the desire for accessible and timely healthcare, positions telepharmacy as a pivotal solution, propelling its adoption and market growth.

Restraint:

Challenges in obtaining licenses across different jurisdictions

Different regulations and licensing requirements in different regions or states demand complex compliance procedures. Telepharmacy services operating across multiple jurisdictions must navigate varied legal frameworks, which often involve rigorous and time-consuming processes for licensure. The need for adherence to distinct regulations complicates operations, increases administrative burdens, and hampers swift market expansion. This challenge of navigating diverse licensing requirements across jurisdictions impedes the seamless delivery of telepharmacy services, limiting geographic reach and scalability.

Opportunity:

Growing awareness regarding the telepharmacy

The increasing awareness surrounding telepharmacy presents a significant opportunity in the market. As remote healthcare solutions grow among patients and healthcare providers, there's heightened recognition of the benefits telepharmacy offers, including improved accessibility to pharmaceutical services, enhanced medication management and expanded healthcare reach, especially in underserved areas. This awareness fosters greater acceptance and adoption of telepharmacy solutions, encouraging both patients and healthcare organizations to embrace these remote services, thereby driving the market's growth and facilitating a more widespread implementation of telepharmacy initiatives.

Threat:

Privacy and data security risks

Handling sensitive patient information remotely increases vulnerability to cyber threats, data breaches and unauthorized access. Protecting patient confidentiality and complying with stringent privacy regulations have become paramount. Mishandling or unauthorized disclosure of health data erodes patient trust and could lead to legal repercussions, which further hinders market expansion.

COVID-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of telepharmacy solutions. The crisis highlighted the need for remote healthcare access, prompting increased reliance on telemedicine and telepharmacy services. Lockdowns, social distancing measures and healthcare facility limitations pushed patients and providers to embrace remote consultations, prescription refills and medication management through telepharmacy platforms. This surge in demand showcased telepharmacy's potential in ensuring continuity of care, shaping a long-term shift towards remote pharmaceutical services.

The patient counselling segment is expected to be the largest during the forecast period

The patient counselling segment is expected to dominate the telepharmacy market due to its pivotal role in medication management and patient-centric care. Telepharmacy facilitates personalized counseling, empowering patients with comprehensive medication guidance, dosage instructions, and adverse effects management. As healthcare increasingly focuses on patient engagement and adherence, telepharmacy's ability to offer remote counseling services, especially for chronic conditions or complex therapies, becomes crucial. This demand for tailored counseling propels the patient counselling segment, emphasizing its significance in ensuring effective pharmaceutical care through telepharmacy services.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to experience substantial growth in the telepharmacy market due to evolving healthcare dynamics. Hospitals increasingly adopt telepharmacy to optimize patient care, streamline medication management, and extend services remotely. The integration of telepharmacy solutions within hospital systems enhances medication adherence and facilitates virtual consultations, especially for discharged patients or those with chronic conditions. Additionally, telepharmacy augments healthcare access, reducing readmission rates and ensuring continuous medication support, positioning the hospitals segment for significant expansion.

Region with largest share:

North America is expected to register the largest market share in the telepharmacy market, owing to its advanced healthcare infrastructure, tech-driven innovation, and mature telehealth landscape. The region boasts robust regulatory frameworks supporting telepharmacy adoption. Furthermore, increased healthcare spending, a growing aging population, and the emphasis on improving healthcare access drive the demand for remote pharmaceutical services. With established telehealth practices and widespread digital connectivity, North America is primed to lead in telepharmacy, leveraging its technological prowess and healthcare advancements to cater to evolving patient needs.

Region with highest CAGR:

Asia Pacific is set to witness substantial growth in the telepharmacy market due to the region's expanding healthcare infrastructure, increasing adoption of digital technology and rising demand for accessible healthcare services. Telepharmacy addresses geographical barriers, especially in remote areas, by offering convenient access to pharmaceutical expertise. Moreover, the region's tech-savvy population and the escalating need for efficient healthcare delivery systems further propel the adoption of telepharmacy solutions, positioning Asia Pacific for lucrative growth in remote pharmaceutical services.

Key players in the market:

Some of the key players in telepharmacy market include Capsule Technologies, CPS Solutions, LLC, Digital Pharmacist Inc., McKesson Ventures, Medication Review, Inc., Medtel Communications, Omnicell, Inc., PharmaPoint, PioneerRx, Pipeline Healthcare, TelePharm (Cardinal Health), Transaction Data Systems, Inc. and ZipDrug.

Key Developments:

In May 2023, OneroRx is pleased to announce that Community Pharmacy of Dunlap is open to serve residents of Dunlap, Iowa, and its surrounding communities. Community Pharmacy has worked closely with Dunlap Community Development Corporation (DCDC) to bring pharmacy services back to the area.

In July 2022, RxLive, a provider of population health pharmacy solutions, today announced a $5 million Series A funding round. The digital health startup's round was led by SpringTide, a healthtech-focused venture capital firm, with participation by Cardinal Health™, a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions in health care. RxLive has raised a total of $8 million to date.

Services Covered:

  • Drug Therapy Monitoring
  • Patient Counselling
  • Refill Authorization for Prescription Drugs
  • Remote Dispensing
  • Other Services

Delivery Modes Covered:

  • On-premises
  • Cloud-based
  • Web-based

Devices Covered:

  • Computers
  • Smartphones
  • Tablets and Kiosk

End Users Covered:

  • Primary Care Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Telepharmacy Market, By Service

  • 5.1 Introduction
  • 5.2 Drug Therapy Monitoring
  • 5.3 Patient Counselling
  • 5.4 Refill Authorization for Prescription Drugs
  • 5.5 Remote Dispensing
  • 5.6 Other Services

6 Global Telepharmacy Market, By Delivery Mode

  • 6.1 Introduction
  • 6.2 On-premises
  • 6.3 Cloud-based
  • 6.4 Web-based

7 Global Telepharmacy Market, By Device

  • 7.1 Introduction
  • 7.2 Computers
  • 7.3 Smartphones
  • 7.4 Tablets and Kiosk

8 Global Telepharmacy Market, By End User

  • 8.1 Introduction
  • 8.2 Primary Care Centers
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Telepharmacy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

11.1 Capsule Technologies

11.2 CPS Solutions, LLC

11.3 Digital Pharmacist Inc.

11.4 McKesson Ventures

11.5 Medication Review, Inc.

11.6 Medtel Communications

11.7 Omnicell, Inc.

11.8 PharmaPoint

11.9 PioneerRx

11.10 Pipeline Healthcare

11.11 TelePharm (Cardinal Health)

11.12 Transaction Data Systems, Inc.

11.13 ZipDrug

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦